Associations Between Diabetes Care and Haptoglobin Genotype On outComes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

3054 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-03-31

Study Completion Date

2020-07-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ADHOC Cohort comprised 3044 DM individuals, treated in 47 CHS primary care clinics, that underwent haptoglobin genotyping between 2 march, 2005 and 26 September 2006. Individuals were eligible for inclusion if they had DM and were 55 years of age or older. All treatment decisions, regarding all aspects of care and follow-up of the study participants, remained at the discretion of the individual's primary care physician, who was blinded to the individual's Hp type. Hp distribution was: Hp 1-1 285 (9.4%); Hp 2-1 1248 (41.0%); Hp 2-2 1511 (49.6%).

Hypothesis: strict glucose control (HbA1c\<7%) reduces the rate of cardiovascular events only to diabetic patients with the Hp 2-2 phenotype. We also postulated that, since Hp 2-2 DM individuals are at an increased genetic susceptibility for cardiovascular disease (CVD), this unique cohort merits an investigation on the associations between various CVD risk variables and CVD events and establish whether any evident association was dependent of the individual's Hp type.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Coronary Artery Plaque Burden in Asymptomatic Danish Men Aged 65-75 Years and the Relation to Glycemic Status.

NCT04525508

Coronary Artery Disease Dysglycemia

COMPLETED

HbA1c as an Early Serologic Marker for the Hemodynamic Progression of Stage A Heart Failure

NCT04450576

Heart Failure, Diastolic

UNKNOWN

Type 2 Diabetes and Bone Microarchitecture

NCT04765631

Type 2 Diabetes

COMPLETED

Gender Differences in Prevalence of Undiagnosed Diabetes in ACS

NCT00589459

Pre-diabetes Diabetes

COMPLETED

Changing the Natural History of Type 2 Diabetes ("CHANGE" Study)

NCT05040087

Type 2 Diabetes

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Cardiovascular Disease Myocardial Infarction Stroke

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diabetic patients
* 55 years old or older at the time of ICARE initiation.
* Known haptoglobin genotype
* Signed informed consent for ICARE study and registry

Minimum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No